# | Title | Journal | Year | Citations |
---|
1 | Radiomics: the bridge between medical imaging and personalized medicine | Nature Reviews Clinical Oncology | 2017 | 3,216 |
2 | Tumour-associated macrophages as treatment targets in oncology | Nature Reviews Clinical Oncology | 2017 | 2,667 |
3 | Delivering nanomedicine to solid tumors | Nature Reviews Clinical Oncology | 2010 | 2,666 |
4 | Tumour heterogeneity and resistance to cancer therapies | Nature Reviews Clinical Oncology | 2018 | 2,149 |
5 | Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease | Nature Reviews Clinical Oncology | 2016 | 1,938 |
6 | EMT, CSCs, and drug resistance: the mechanistic link and clinical implications | Nature Reviews Clinical Oncology | 2017 | 1,865 |
7 | Targeting the IL-6/JAK/STAT3 signalling axis in cancer | Nature Reviews Clinical Oncology | 2018 | 1,789 |
8 | Chimeric antigen receptor T-cell therapy — assessment and management of toxicities | Nature Reviews Clinical Oncology | 2018 | 1,659 |
9 | Clinical development and potential of photothermal and photodynamic therapies for cancer | Nature Reviews Clinical Oncology | 2020 | 1,622 |
10 | The immune contexture in cancer prognosis and treatment | Nature Reviews Clinical Oncology | 2017 | 1,590 |
11 | Liquid biopsy: monitoring cancer-genetics in the blood | Nature Reviews Clinical Oncology | 2013 | 1,482 |
12 | Integrating liquid biopsies into the management of cancer | Nature Reviews Clinical Oncology | 2017 | 1,375 |
13 | Molecular therapies and precision medicine for hepatocellular carcinoma | Nature Reviews Clinical Oncology | 2018 | 1,308 |
14 | MicroRNAs in body fluids—the mix of hormones and biomarkers | Nature Reviews Clinical Oncology | 2011 | 1,290 |
15 | Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance | Nature Reviews Clinical Oncology | 2019 | 1,235 |
16 | Broadening horizons: the role of ferroptosis in cancer | Nature Reviews Clinical Oncology | 2021 | 1,216 |
17 | Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges | Nature Reviews Clinical Oncology | 2018 | 1,192 |
18 | Targeting apoptosis in cancer therapy | Nature Reviews Clinical Oncology | 2020 | 1,192 |
19 | Image-guided cancer surgery using near-infrared fluorescence | Nature Reviews Clinical Oncology | 2013 | 1,121 |
20 | Cancer immunoediting and resistance to T cell-based immunotherapy | Nature Reviews Clinical Oncology | 2019 | 1,093 |
21 | Patient-derived tumour xenografts as models for oncology drug development | Nature Reviews Clinical Oncology | 2012 | 1,091 |
22 | Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update | Nature Reviews Clinical Oncology | 2015 | 1,053 |
23 | Cholangiocarcinoma — evolving concepts and therapeutic strategies | Nature Reviews Clinical Oncology | 2018 | 1,051 |
24 | Cancer metabolism: a therapeutic perspective | Nature Reviews Clinical Oncology | 2017 | 1,028 |
25 | Extracellular vesicles in cancer — implications for future improvements in cancer care | Nature Reviews Clinical Oncology | 2018 | 1,020 |
26 | Cancer-related fatigue—mechanisms, risk factors, and treatments | Nature Reviews Clinical Oncology | 2014 | 998 |
27 | NTRK fusion-positive cancers and TRK inhibitor therapy | Nature Reviews Clinical Oncology | 2018 | 975 |
28 | Targeted agents and immunotherapies: optimizing outcomes in melanoma | Nature Reviews Clinical Oncology | 2017 | 945 |
29 | Clinical relevance of circulating cell-free microRNAs in cancer | Nature Reviews Clinical Oncology | 2014 | 915 |
30 | The future of cancer treatment: immunomodulation, CARs and combination immunotherapy | Nature Reviews Clinical Oncology | 2016 | 909 |
31 | Inflammation and cancer: advances and new agents | Nature Reviews Clinical Oncology | 2015 | 901 |
32 | Current state of immunotherapy for glioblastoma | Nature Reviews Clinical Oncology | 2018 | 873 |
33 | Regulatory T cells in cancer immunosuppression — implications for anticancer therapy | Nature Reviews Clinical Oncology | 2019 | 872 |
34 | Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways | Nature Reviews Clinical Oncology | 2011 | 870 |
35 | Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination | Nature Reviews Clinical Oncology | 2016 | 831 |
36 | EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood | Nature Reviews Clinical Oncology | 2021 | 826 |
37 | Artificial intelligence in digital pathology — new tools for diagnosis and precision oncology | Nature Reviews Clinical Oncology | 2019 | 807 |
38 | Treating cancer with selective CDK4/6 inhibitors | Nature Reviews Clinical Oncology | 2016 | 806 |
39 | Imaging biomarker roadmap for cancer studies | Nature Reviews Clinical Oncology | 2017 | 792 |
40 | Oligometastases revisited | Nature Reviews Clinical Oncology | 2011 | 787 |
41 | Monitoring immune-checkpoint blockade: response evaluation and biomarker development | Nature Reviews Clinical Oncology | 2017 | 787 |
42 | Engineering strategies to overcome the current roadblocks in CAR T cell therapy | Nature Reviews Clinical Oncology | 2020 | 786 |
43 | Targeting the PI3K pathway in cancer: are we making headway? | Nature Reviews Clinical Oncology | 2018 | 762 |
44 | Radiotherapy and immunotherapy: a beneficial liaison? | Nature Reviews Clinical Oncology | 2017 | 760 |
45 | Combination cancer immunotherapies tailored to the tumour microenvironment | Nature Reviews Clinical Oncology | 2016 | 753 |
46 | Acquired resistance to TKIs in solid tumours: learning from lung cancer | Nature Reviews Clinical Oncology | 2014 | 740 |
47 | Microsatellite instability in colorectal cancer—the stable evidence | Nature Reviews Clinical Oncology | 2010 | 736 |
48 | State-of-the-art strategies for targeting the DNA damage response in cancer | Nature Reviews Clinical Oncology | 2019 | 736 |
49 | Treatment of HER2-positive breast cancer: current status and future perspectives | Nature Reviews Clinical Oncology | 2012 | 735 |
50 | Understanding the mechanisms and treatment options in cancer cachexia | Nature Reviews Clinical Oncology | 2013 | 729 |